nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

07.01.2021 | Original Article

Role of [⁶⁸Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of peritoneal carcinomatosis and comparison with [¹⁸F]-FDG PET/CT

verfasst von: Liang Zhao, Yizhen Pang, Zuoming Luo, Kaili Fu, Tingting Yang, Long Zhao, Long Sun, Hua Wu, Qin Lin, Haojun Chen

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to explore the role of [⁶⁸Ga]Ga-DOTA-FAPI-04 positron emission tomography/computed tomography (PET/CT), compared with ¹⁸F-fluorodeoxyglucose [¹⁸F]-FDG PET/CT, for evaluating peritoneal carcinomatosis in patients with various types of cancer.

Methods

Patients with suspected peritoneal malignancy, who underwent both [¹⁸F]-FDG and [⁶⁸Ga]Ga-DOTA-FAPI-04 PET/CT between October 2019 and August 2020, were retrospectively analysed. The radiotracer uptake, peritoneal cancer index (PCI) score, and diagnostic performance of [¹⁸F]-FDG and [⁶⁸Ga]Ga-DOTA-FAPI-04 PET/CT were evaluated and compared.

Results

Our cohort consisted of 46 patients, including 16 patients with diffuse-type peritoneal carcinomatosis, 27 with nodular-type peritoneal carcinomatosis, and 3 true-negative patients. A significant difference in standard uptake values (SUV) of lesions between [¹⁸F]-FDG and [⁶⁸Ga]Ga-DOTA-FAPI-04 PET/CT examination was observed (median SUV: 3.48 vs. 9.82; P < 0.001), particularly in peritoneal carcinomatosis from gastric cancer (median SUV: 3.44 vs. 8.05; P = 0.001). Moreover, [⁶⁸Ga]Ga-DOTA-FAPI-04 PET/CT showed a higher PCI score and better sensitivity than [¹⁸F]-FDG PET/CT for the detection of peritoneal carcinomatosis (6 vs. 18; P < 0.001; 72.09% vs. 97.67%; P = 0.002).

Conclusion

[⁶⁸Ga]Ga-DOTA-FAPI-04 PET/CT demonstrated superior sensitivity over [¹⁸F]-FDG PET/CT for the detection of peritoneal carcinomatosis in patients with various types of cancer, particularly gastric cancer. Furthermore, the uptake of [⁶⁸Ga]Ga-DOTA-FAPI-04 in peritoneal carcinomatosis was significantly higher than that of [¹⁸F]-FDG, demonstrating a larger extent of the lesions and yielding a higher PCI score. This could help enhance the image contrast, improve physicians’ diagnostic confidence, and reduce the proportion of missed diagnoses.

Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70. https://doi.org/10.1016/s0092-8674(00)81683-9.CrossRefPubMed

Glehen O, Osinsky D, Cotte E, Kwiatkowski F, Freyer G, Isaac S, et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol. 2003;10(8):863–9. https://doi.org/10.1245/aso.2003.01.018.CrossRefPubMed

Cashin PH, Mahteme H, Spang N, Syk I, Frodin JE, Torkzad M, et al. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: a randomised trial. Eur J Cancer. 2016;53:155–62. https://doi.org/10.1016/j.ejca.2015.09.017.CrossRefPubMed

Jacobson R, Sherman SK, Dahdaleh F, Turaga KK. Peritoneal metastases in colorectal cancer. Ann Surg Oncol. 2018;25(8):2145–51. https://doi.org/10.1245/s10434-018-6490-x.CrossRefPubMed

Froysnes IS, Andersson Y, Larsen SG, Davidson B, Oien JT, Julsrud L, et al. ImmunoPeCa trial: long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis. Eur J Surg Oncol. 2019. https://doi.org/10.1016/j.ejso.2019.04.014.

Alyami M, Hubner M, Grass F, Bakrin N, Villeneuve L, Laplace N, et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol. 2019;20(7):e368–e77. https://doi.org/10.1016/S1470-2045(19)30318-3.CrossRefPubMed

Marin D, Catalano C, Baski M, Di Martino M, Geiger D, Di Giorgio A, et al. 64-Section multi-detector row CT in the preoperative diagnosis of peritoneal carcinomatosis: correlation with histopathological findings. Abdom Imaging. 2010;35(6):694–700. https://doi.org/10.1007/s00261-008-9464-9.CrossRefPubMed

Gryspeerdt S, Clabout L, Van Hoe L, Berteloot P, Vergote IB. Intraperitoneal contrast material combined with CT for detection of peritoneal metastases of ovarian cancer. Eur J Gynaecol Oncol. 1998;19(5):434–7.PubMed

Brizi MG, Natale L, Manfredi R, Barbaro B, Vecchioli A, Marano P. Staging of pancreatic ductal adenocarcinoma with spiral CT and MRI. Rays. 2001;26(2):151–9.PubMed

10.

Low RN. MR imaging of the peritoneal spread of malignancy. Abdom Imaging. 2007;32(3):267–83. https://doi.org/10.1007/s00261-007-9210-8.CrossRefPubMed

11.

Kostakoglu L, Agress H Jr, Goldsmith SJ. Clinical role of FDG PET in evaluation of cancer patients. Radiographics. 2003;23(2):315–40; quiz 533. https://doi.org/10.1148/rg.232025705.CrossRefPubMed

12.

Kim SJ, Lee SW. Diagnostic accuracy of (18)F-FDG PET/CT for detection of peritoneal carcinomatosis; a systematic review and meta-analysis. Br J Radiol. 2018;91(1081):20170519. https://doi.org/10.1259/bjr.20170519.CrossRefPubMed

13.

Suzuki A, Kawano T, Takahashi N, Lee J, Nakagami Y, Miyagi E, et al. Value of 18F-FDG PET in the detection of peritoneal carcinomatosis. Eur J Nucl Med Mol Imaging. 2004;31(10):1413–20. https://doi.org/10.1007/s00259-004-1577-y.CrossRefPubMed

14.

Lopez-Lopez V, Cascales-Campos PA, Gil J, Frutos L, Andrade RJ, Fuster-Quinonero M, et al. Use of (18)F-FDG PET/CT in the preoperative evaluation of patients diagnosed with peritoneal carcinomatosis of ovarian origin, candidates to cytoreduction and hipec. A pending issue. Eur J Radiol. 2016;85(10):1824–8. https://doi.org/10.1016/j.ejrad.2016.08.006.CrossRefPubMed

15.

Soyka JD, Strobel K, Veit-Haibach P, Schaefer NG, Schmid DT, Tschopp A, et al. Influence of bowel preparation before 18F-FDG PET/CT on physiologic 18F-FDG activity in the intestine. J Nucl Med. 2010;51(4):507–10. https://doi.org/10.2967/jnumed.109.071001.CrossRefPubMed

16.

Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16(9):582–98. https://doi.org/10.1038/nrc.2016.73.CrossRefPubMed

17.

Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2019;18(2):99–115. https://doi.org/10.1038/s41573-018-0004-1.CrossRefPubMed

18.

Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, et al. (68)Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60(6):801–5. https://doi.org/10.2967/jnumed.119.227967.CrossRefPubMedPubMedCentral

19.

Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59(9):1415–22. https://doi.org/10.2967/jnumed.118.210443.CrossRefPubMed

20.

Chen H, Pang Y, Wu J, Zhao L, Hao B, Wu J, et al. Comparison of [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging. 2020. https://doi.org/10.1007/s00259-020-04769-z.

21.

Chen H, Zhao L, Ruan D, Pang Y, Hao B, Dai Y, et al. Usefulness of [(68)Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [(18)F]FDG PET/CT findings. Eur J Nucl Med Mol Imaging. 2020. https://doi.org/10.1007/s00259-020-04940-6.

22.

Zhao L, Zhuang Y, Fu K, Chen P, Wang Y, Zhuo J, et al. Usefulness of [(18)F]fluorodeoxyglucose PET/CT for evaluating the PD-L1 status in nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2020. https://doi.org/10.1007/s00259-019-04654-4.

23.

Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221(1):29–42. https://doi.org/10.1097/00000658-199501000-00004.CrossRefPubMedPubMedCentral

24.

Pletcher E, Gleeson E, Labow D. Peritoneal cancers and hyperthermic intraperitoneal chemotherapy. Surg Clin North Am. 2020;100(3):589–613. https://doi.org/10.1016/j.suc.2020.02.009.CrossRefPubMed

25.

van Baal J, van Noorden CJF, Nieuwland R, Van de Vijver KK, Sturk A, van Driel WJ, et al. Development of peritoneal carcinomatosis in epithelial ovarian cancer: a review. J Histochem Cytochem. 2018;66(2):67–83. https://doi.org/10.1369/0022155417742897.CrossRefPubMed

26.

Raptopoulos V, Gourtsoyiannis N. Peritoneal carcinomatosis. Eur Radiol. 2001;11(11):2195–206. https://doi.org/10.1007/s003300100998.CrossRefPubMed

27.

Akin EA, Qazi ZN, Osman M, Zeman RK. Clinical impact of FDG PET/CT in alimentary tract malignancies: an updated review. Abdom Radiol (NY). 2020;45(4):1018–35. https://doi.org/10.1007/s00261-020-02447-0.CrossRef

28.

Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74. https://doi.org/10.1007/978-1-4613-1247-5_23.CrossRefPubMed

29.

Archer AG, Sugarbaker PH, Jelinek JS. Radiology of peritoneal carcinomatosis. Cancer Treat Res. 1996;82:263–88. https://doi.org/10.1007/978-1-4613-1247-5_17.CrossRefPubMed

30.

Mo S, Cai G. Multidisciplinary treatment for colorectal peritoneal metastases: review of the literature. Gastroenterol Res Pract. 2016;2016:1516259. https://doi.org/10.1155/2016/1516259.CrossRefPubMedPubMedCentral

31.

Abdalla Ahmed S, Abou-Taleb H, Ali N, MB D. Accuracy of radiologic- laparoscopic peritoneal carcinomatosis categorization in the prediction of surgical outcome. Br J Radiol. 2019;92(1100):20190163. https://doi.org/10.1259/bjr.20190163.CrossRefPubMedPubMedCentral

32.

Elzarkaa AA, Shaalan W, Elemam D, Mansour H, Melis M, Malik E, et al. Peritoneal cancer index as a predictor of survival in advanced stage serous epithelial ovarian cancer: a prospective study. J Gynecol Oncol. 2018;29(4):e47. https://doi.org/10.3802/jgo.2018.29.e47.CrossRefPubMedPubMedCentral

33.

Chang MC, Chen JH, Liang JA, Huang WS, Cheng KY, Kao CH. PET or PET/CT for detection of peritoneal carcinomatosis: a meta-analysis. Clin Nucl Med. 2013;38(8):623–9. https://doi.org/10.1097/RLU.0b013e318299609f.CrossRefPubMed

34.

Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v38–49. https://doi.org/10.1093/annonc/mdw350.CrossRefPubMed

35.

Lim JS, Kim MJ, Yun MJ, Oh YT, Kim JH, Hwang HS, et al. Comparison of CT and 18F-FDG pet for detecting peritoneal metastasis on the preoperative evaluation for gastric carcinoma. Korean J Radiol. 2006;7(4):249–56. https://doi.org/10.3348/kjr.2006.7.4.249.CrossRefPubMedPubMedCentral

36.

Honma Y, Terauchi T, Tateishi U, Kano D, Nagashima K, Shoji H, et al. Imaging peritoneal metastasis of gastric cancer with (18)F-fluorothymidine positron emission tomography/computed tomography: a proof-of-concept study. Br J Radiol. 2018;91(1089):20180259. https://doi.org/10.1259/bjr.20180259.CrossRefPubMedPubMedCentral

37.

Yoshioka T, Yamaguchi K, Kubota K, Saginoya T, Yamazaki T, Ido T, et al. Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer. J Nucl Med. 2003;44(5):690–9.PubMed

38.

Capobianco A, Cottone L, Monno A, Manfredi AA, Rovere-Querini P. The peritoneum: healing, immunity, and diseases. J Pathol. 2017;243(2):137–47. https://doi.org/10.1002/path.4942.CrossRefPubMed

39.

Lv ZD, Wang HB, Li FN, Wu L, Liu C, Nie G, et al. TGF-beta1 induces peritoneal fibrosis by activating the Smad2 pathway in mesothelial cells and promotes peritoneal carcinomatosis. Int J Mol Med. 2012;29(3):373–9. https://doi.org/10.3892/ijmm.2011.852.CrossRefPubMed

40.

Turlakow A, Yeung HW, Salmon AS, Macapinlac HA, Larson SM. Peritoneal carcinomatosis: role of (18)F-FDG PET. J Nucl Med. 2003;44(9):1407–12.PubMed

41.

Calais J, Mona CE. Will FAPI PET/CT Replace FDG PET/CT in the next decade?-point: an important diagnostic, phenotypic and biomarker role. AJR Am J Roentgenol. 2020. https://doi.org/10.2214/AJR.20.24302.

Titel: Role of [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of peritoneal carcinomatosis and comparison with [18F]-FDG PET/CT
verfasst von: Liang Zhao
Yizhen Pang
Zuoming Luo
Kaili Fu
Tingting Yang
Long Zhao
Long Sun
Hua Wu
Qin Lin
Haojun Chen
Publikationsdatum: 07.01.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 6/2021
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-020-05146-6

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Role of [⁶⁸Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of peritoneal carcinomatosis and comparison with [¹⁸F]-FDG PET/CT

Abstract

Purpose

Methods

Results

Conclusion

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2021

Sequential implementation of DSC-MR perfusion and dynamic [18F]FET PET allows efficient differentiation of glioma progression from treatment-related changes

Quantification of perivascular inflammation does not provide incremental prognostic value over myocardial perfusion imaging and calcium scoring

Correction to: 68Ga-FAPI outperforms 18F-FDG PET/CT in identifying solitary fibrous tumor

Diagnostic value of [18F]FDG-PET/CT in polymyalgia rheumatica: a systematic review and meta-analysis

Biodistribution, pharmacokinetics, dosimetry of [68Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [18F]F-FDG PET/CT in patients with various cancers

Advanced analytics and artificial intelligence in gastrointestinal cancer: a systematic review of radiomics predicting response to treatment